中文产业新闻· 新浪网·· 22 hours agoPickScore80
Aulin Biotech Recombinant Staphylococcus aureus Vaccine Shows 73.25% Protective Efficacy in Late-Stage Trial
In brief
Aulin Biotech (688319.SH) says the final report of the late-stage clinical study of its recombinant Staphylococcus aureus vaccine shows protective efficacy of 73.25% against S. aureus infection within 42 days after closed fracture surgery. The vaccine completed late-stage unblinding in July 2026, and the company recently received the final report.
Why it matters
The report gives a specific efficacy figure, 73.25% within 42 days after closed fracture surgery, allowing direct comparison with other S. aureus vaccines.
Source: 中文产业新闻 · finance.sina.com.cn